Multiplexed Cell- and Bead-based Assays in a No-wash Format for Biologics Screening and Characterization
Poster Jul 08, 2016
David Onley, Lucy Chammas, Diana Caracino and Paul G. Wylie
Biologics such as antibodies are ideally suited for therapeutic use against cell-surface disease targets. When screening, the use of cells expressing native target proteins minimises the risk of false positive
binding (which can occur when using recombinant proteins) leading to improved hit quality.
Traditional screening methods to identify and characterise hits often report a single measurement per well, due to either assay or instrumentation constraints. Multiplexed assay formats facilitate the reporting of multiple readouts to further improve data quality and enhance productivity, whilst also conserving sample. Here we present the results generated from multiplexed no-wash protocols using TTP Labtech’s mirrorball, a laser scanning cytometer. To model antibody screening, anti-EGFR antibodies were titrated against multiplexed target-expressing and control cells to determine specific versus non-specific binding in one productive screen. Additionally, we report the results of a no wash, IL-6 and IL-8 cytokine detection assay where reagents from two commercially available single-plex ELISA kits were transferred onto TTP Labtech sol-R™ coded beads and multiplexed together. The results of this alternative fluorescence-based approach demonstrate similar performance to ELISA, but with a significantly streamlined work-flow.
Overall, the data presented here show the versatile nature of and advantages of multiplexing assays using TTP Labtech’s mirrorball for improving the productivity of biologics discovery.
Histone Deacetylase 6 (HDAC6) As A Therapeutic Target in Chronic Lymphocytic LeukemiaPoster
This study investigates the role of histone deacetylase 6 (HDAC6) in chronic lymphocytic leukemia and establishes it as a novel therapeutic target for the treatment of this disease.READ MORE
Improved T Cell Activation Bioassays for Development of Bispecific Antibodies and Engineered T Cell ImmunotherapiesPoster
Here we describe a platform of T cell activation bioassays for the development of CD3 bispecific antibodies and engineered T cell immunotherapies.READ MORE
Quantitative Cell-Based Bioassays for Individual or Combination Immune Checkpoint ImmunotherapyPoster
Cell-based reporter bioassays overcome the limitations of primary cell-based assays for functional characterization of antibody and other biologics drugs targeting individual or combination immune checkpoint receptors. Here we show a portfolio of immune inhibitory checkpoint bioassays targeting PD-1/PD-L1, TIGIT/CD155, CTLA4/CD80/86 and LAG3/MHCII, that can be used for antibody screening, characterization, potency and stability studies.READ MORE